Wu Minyuan

専門分野: Pediatric hematologist
76年の経験
勤務先: 中国, 北京, Beijing Jingdu Children’s Hospital
As a specialist at the clinic, Dr. Wu Minyuan is a Professor, Chief Physician, and Doctoral Supervisor specializing in pediatric hematology at Beijing Jingdu Children’s Hospital. She is described as a pioneer in childhood leukemia treatment and a key figure in advancing China’s pediatric hematology standards, with over 50 years of clinical and academic leadership. A major differentiator is her guideline and protocol leadership: as former Director of the Hematology Center at Beijing Children’s Hospital, she spearheaded national protocols that elevated 5-year disease-free survival for pediatric acute lymphoblastic leukemia (ALL) to over 80%. Her profile also lists 1970 graduation from Capital Medical University’s Department of Pediatrics and contributions including risk-stratified chemotherapy and multi-center trials integrating chemotherapy, immunotherapy, and targeted therapies.
Dr. Wu Minyuan is a specialist at the clinic and a Professor/Chief Physician/Doctoral Supervisor in pediatric hematology at Beijing Jingdu Children’s Hospital. She has over 50 years of clinical and academic leadership and is described as a pioneer in childhood leukemia treatment. Her differentiator is protocol leadership: as former Director of the Hematology Center at Beijing Children’s Hospital, she spearheaded national protocols that raised 5-year disease-free survival for pediatric ALL to over 80%, alongside work on risk-stratified chemotherapy and multi-center trials integrating chemotherapy, immunotherapy, and targeted therapies.

医師のサービス

調子はいかがですか？

1 の 3

この医師の情報は完全で明確です

強く反対

強く賛成

資格

Dr. Wu Minyuan’s career is centered on pediatric leukemia outcomes—especially through national protocol development and risk-stratified treatment strategies. As a specialist at the clinic, she is a Professor, Chief Physician, and Doctoral Supervisor specializing in pediatric hematology at Beijing Jingdu Children’s Hospital. Her profile describes over 50 years of clinical and academic leadership and positions her as a pioneer in childhood leukemia treatment and a key figure in advancing China’s pediatric hematology standards. She graduated from Capital Medical University’s Department of Pediatrics in 1970. As former Director of the Hematology Center at Beijing Children’s Hospital, she spearheaded national protocols that elevated 5-year disease-free survival for pediatric acute lymphoblastic leukemia (ALL) to over 80%. Her work also includes developing multi-center clinical trials integrating chemotherapy, immunotherapy, and targeted therapies, and she serves as Chief Editor of Diagnostic and Treatment Guidelines for Pediatric Hematologic Diseases (national standard).

Education

Capital Medical University — Department of Pediatrics (1970 graduate).

Work experience

Professor, Chief Physician, and Doctoral Supervisor — pediatric hematology, Beijing Jingdu Children’s Hospital.
Former Director — Hematology Center, Beijing Children’s Hospital.

Clinical focus and techniques

Dr. Wu Minyuan focuses on pediatric hematology with emphasis on leukemia protocols and survivorship considerations.

Risk-stratified chemotherapy for pediatric ALL.
Multi-center clinical trials integrating chemotherapy, immunotherapy, and targeted therapies.
Guideline development for pediatric hematologic diseases (national standard).
Evidence-based protocols for nutritional anemia and refractory ITP management.

Professional societies and certifications

No specific certifications are listed in the provided materials.

Academic output

Her profile lists contributions including 30+ peer-reviewed papers and 5 clinical guidelines.

Courses and advanced training

No named courses are specified in the provided materials.

Awards and recognition

No specific awards are listed in the provided materials.

For international patients, the clinic’s pediatric hematology consultation supports protocol-based management for leukemia and other blood disorders. Dr. Wu Minyuan’s work includes both treatment strategy development and survivorship studies, reflecting attention to long-term outcomes after pediatric ALL.